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lumbar radicular pain and disc herniation are
associated with a sex - OPRM1 A118G
polymorphism interaction: a prospective 1-year
observational study
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and Johannes Gjerstad1,3,5Abstract
Background: Earlier observations show that development of persistent pain may be associated with the genetic
variability in the gene encoding for the μ-opioid receptor 1, the OPRM1 A118G (rs1799971). The aim of this study
was to investigate the association between OPRM1 genotype and subjective health complaints in patients with
radicular pain and disc herniation.
Methods: A prospective, 1-year observational study was conducted at a hospital back clinic, including 118 Caucasian
patients with lumbar radicular pain and MRI confirmed disc herniation. Single nucleotide polymorphism genotyping
regarding the OPRM1 A118G was performed. The data of individuals with AA versus AG or GG were analysed
separately by linear mixed models. The Subjective Health Complaints Inventory (0-81) including 27 common
complaints experienced the previous month on a scale from not at all (0) to severe (3) was used as outcome.
Pain, prior duration of leg pain, age, smoking status, and lumbar disc surgery were considered as covariates.
Results: In total 23 of 118 patients were carriers of the OPRM1 G-allele. All patients except female carriers of the
G-allele reported a decrease in pain from baseline to 1 year. Female carriers of the G-allele reported significantly
higher subjective health complaints score during the study time span than male carriers of the G-allele when
controlling for pain and pain duration.
Conclusion: The present data indicate that, when controlling for pain intensity and duration, subjective health
complaints are associated with a sex - OPRM1 A118G polymorphism interaction in patients with radicular pain.
Keywords: μ-opioid receptor 1, Sex, Subjective health complaints, Sciatica, Radiculopathy, OPRM1 A118G, rs1799971Background
Patients with non-specific low back pain or lumbar radicu-
lar pain often report additional subjective health com-
plaints [1-4]. In the literature such health complaints have
also been referred to as multiple physical symptoms, func-
tional somatic syndrome, medically unexplained symptoms
or somatisation [5-8], and include report of headaches,* Correspondence: eivhas@so-hf.no
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unless otherwise stated.pain, dyspnoea, gastrointestinal discomfort, anxiety and
sadness [9]. In patients with lumbar radicular pain, previ-
ous work has shown that subjective health complaints may
be associated with the severity of pain-related disability [2]
and unfavourable outcome at 1 and 2 years follow-up [10].
The single nucleotide polymorphism (SNP) in the human
gene coding for the μ-opioid receptor 1, the OPRM1 A118G
(rs1799971), may affect nociceptive signalling. For example,
carriers of the G-allele seem to have less pronounced effects
of opioids [11-15], increased pressure pain thresholds [16]
and reduced cortical responses to nociceptive olfactory CO2Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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However, the G-allele has been associated with higher pain
ratings and amount of self-administered intravenous mor-
phine in women after caesarean section [18,19]. Moreover,
female carriers of the G-allele suffering from lumbar radicu-
lar pain and disc herniation reported significantly higher
pain levels than males with the same genotype [20].
Of relevance to comorbid symptoms, the OPRM1
polymorphism has been associated with other physio-
logical processes such as immune and inflammatory
function [21,22], stress response [23,24], substance abuse
[25], social attachment [26], social sensitivity to rejection
[27], and reward mechanisms [28,29]. However, there is a
scarcity of comparable genetic work done on the report of
subjective health complaints. Hence, the aim of the
present study was to investigate how this genetic vari-
ant affects such comorbid symptoms in patients with
lumbar disc herniation and radicular pain. Previous
data have demonstrated sex differences between male
and female G-allele carriers regarding pain [20]. Our
hypothesis was therefore that the effect of the OPRM1
G-allele could be different in men and women regard-
ing the report of subjective health complaints.
Methods
Patients, setting and procedures
This study was part of a prospective, 1 year observational
study on patients with suspected lumbar radicular pain
and disc herniation who were referred to a back clinic at
Oslo University Hospital, Ullevål (OUS), Norway, during
2007 to 2009. Patients were invited to participate by the
clinic staff. Inclusion criteria were age 18-60 years, lumbar
radicular leg pain with a corresponding lumbar disc her-
niation at the relevant side and level confirmed by mag-
netic resonance imaging, and positive straight leg raise
test (defined as radiating pain below the knee, within 60°
elevation). Exclusion criteria were lumbar spinal stenosis,
previous disc surgery at the same level, lumbar spine
fusion at any level, generalised musculoskeletal pain,
inflammatory rheumatic disease, diabetic polyneurop-
athy, cardiovascular disease, cancer, psychiatric disease,
neurological disease, alcohol or drug abuse, completion
of another surgery within 1 month, pregnancy, non-
detectable genotype, non-European-Caucasian ethni-
city or poor Norwegian language. Patients received a
standard clinical examination and answered a compre-
hensive questionnaire at baseline and at 1 year. Blood
samples were taken at inclusion.
Treatment followed practice as usual, without any pre-
allocation or randomisation. The conservative manage-
ment options comprised a brief cognitive intervention, ac-
tivity guidance during the acute phase, and physiotherapy.
The choice of conservative and/or surgical treatment was
made at the discretion of each physician/surgeon. Allparticipants received written information and signed
an informed consent form. The study was approved by
the Norwegian Regional Committee for Medical Re-
search Ethics and the Norwegian Social Science Data
Services.Measurements
The number and severity of health complaints was mea-
sured by the Subjective Health Complaints Inventory
(SHC) [9]. This questionnaire consists of 29 common
somatic and psychological complaints, such as pain (6
items), headache, dyspnoea, gastrointestinal discomfort,
anxiety and sadness (see Additional file 1 for full over-
view of questionnaire items). Participants grade the inten-
sity of each complaint experienced during the previous
month on a 0-3 scale with the categories; not at all, a lit-
tle, some, and severe. The SHC score is calculated by sum-
mation of item scores. The items leg pain during physical
activity and low back pain are closely related to the pa-
tient’s present pain complaint and consequently ex-
cluded in all analyses, making the total possible score
81. Data on SHC prevalence in the Norwegian general
population [30] as well as comparisons with clinical
samples have been published [2,4,31]. Pain severity was
assessed by a 10-point numeric scale with endpoints
no pain and worst possible pain, indicating pain in ac-
tivity during the last week, as used previously [20]. Pa-
tients also reported duration of their leg pain prior to
baseline. At inclusion the socio-demographic variables
age, sex and smoking status were recorded.Genotyping
Genotyping was performed after finished patient sam-
pling. Genomic DNA was extracted from whole blood
cells using FlexiGene DNA isolation kit (Qiagen), and
single nucleotide polymorphism (SNP) genotyping was
performed using predesigned TaqMan SNP genotyping
assays (Applied Biosystems). Approximately 10 ng of gen-
omic DNA was amplified in 5 μl reaction mixture using a
384-well plate containing 1x TaqMan genotyping master
mix (Applied Biosystems) and 1x assay mix. The latter
contained the respective primers and probes. Probes were
labelled with the TaqMan reporter dyes Fam™ and Vic® to
distinguish between the OPRM1 alleles, A or G. After ini-
tial denaturation and enzyme activation at 95°C for
10 min, the reaction mixture was subjected to 60 cycles of
95°C for 15 seconds and 60°C for 1 min. The reactions
were performed on an ABI 7900HT sequence detection
system. Negative controls containing water instead of
DNA were included in every run. Genotypes were deter-
mined using the SDS 2.2 software (Applied Biosystems).
Approximately 10% of the samples were re-genotyped,
and the concordance rate was 100%.
Table 1 Parameter estimates for predictors in the final
linear mixed-effects regression model, with SHC during
the study time span† as outcome (n = 23)
b SE 95% CI p
Estimates of fixed effects
Female *G carrier (male *G) 6.59 2.37 1.2, 11.37 0.008
Pain score (0-10)† 0.92 0.39 0.12, 1.72 0.025
Pain duration (weeks) 0.14 0.05 0.04, 0.25 0.010
Time 1 year (baseline) 1.91 1.13 −0.42, 4.24 0.103
Estimates of covariance parameters
Residual 9.19 3.04 4.80, 17.59 0.003
Random effects 1.75 0.65 0.85, 3.63 0.007
Reference category or scale in brackets. †Both baseline and 1-year scores were
included in the analysis.
Table 2 Patient characteristics according to sex and
genotype
OPRM1 AA genotype OPRM1 *G genotype
Men Women Men Women
N 36 59 14 9
Age 42.9 (10.3) 39.6 (9.5) 42.4 (10.8) 43.2 (8.9)
SHC baseline 14.67 (9.63) 13.29 (8.55) 10.10 (9.38) 16.22 (8.67)
SHC 1 year 13.61 (12.50) 12.73 (10.02) 6.97 (6.01) 18.88 (12.23)
Pain baseline 6.07 (2.68) 5.66 (2.66) 5.68 (3.14) 5.17 (2.50)
Pain 1 year 3.84 (3.12) 3.12 (2.90) 1.53 (2.65) 5.41 (2.32)
Duration (weeks) 22.6 (18.9) 33.3 (30.9) 17.5 (14.5) 40.7 (37.8)
Smoker 50% 27% 36% 44%
Surgery 44% 37% 36% 33%
Values presented as means with standard deviation (SD).
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Genotypes were dichotomised into AA carriers (partic-
ipants with homozygous A-alleles) or *G carriers (par-
ticipants with heterozygous A/G-alleles or homozygous
G-alleles) because only one patient was homozygous GG.
Analyses were performed separately for female *G versus
male *G carriers, female AA versus female *G carriers,
male AA versus male *G carriers, as well as female AA
versus male AA carriers, using a linear mixed effects
model approach. The outcome variable was SHC during
the study time span. Both baseline and 1-year scores were
included in the model. This was done to examine change
over time by testing interactions between SHC and time.
Pain, as measured at baseline and 1 year, duration of leg
pain prior to inclusion, age, smoking status, and lumbar
disc surgery during the follow-up were tested in univariate
analyses. Multivariate analyses were built by including var-
iables from the univariate analyses with p < 0.1. The base-
line model consisted of the fixed factors shown in Table 1.
Subsequent models tested random intercept, and random
slope for pain intensity. The decision to test for random
effects of pain was based on previous work showing geno-
type differences in pain intensity over time [20]. Subject-
specific random factors and covariance structure was
based on a best fit approach, assessed by the small-sample
version of Akaike’s information criteria (AICc) [32]. The
final model random factors included random intercept,
and random slope for pain intensity. Scaled identity co-
variance structure for the random factors was used. Esti-
mation was done by maximum likelihood. No centring or
imputation was performed. Analyses were assessed for ad-
herence to linear mixed effect model assumptions. The
four comparisons were corrected with the Bonferroni
method. A p value < 0.0125 (0.05/4) was chosen as the sig-
nificance level. Analyses were done using SPSS version
21.0 (IBM Corp., Armonk, NY).
Results
In total, 118 patients were included in the study of whom
112 (95%) completed the 1-year follow-up. 23 patients
were carriers of the OPRM1 G-allele, corresponding to a
G-allele frequency of 10.2% in total (14% among males,
7.3% among females). One woman was homozygous GG.
Patient characteristics according to sex and genotype
are presented in Table 2. All patients except the female
*G-carriers reported a decrease in pain from baseline
to 1 year. Figure 1 illustrates the SHC and pain scores
at baseline and 1 year according to sex and genotype.
The results from the final linear mixed model, includ-
ing pain intensity and duration, showed that female *G
carriers had significantly higher SHC score than male *G
carriers, F (1, 44) = 7.73, p = 0.008. This effect of sex had
a clear influence on SHC (b = 6.59, 95% CI 1.2, 11.37),
whereas the effect of pain (b = 0.92, 95% CI 0.12, 1.72,p = 0.025) and prior pain duration (b = 0.14, 95% CI 0.04,
0.025, p = 0.01) was less pronounced. The subject-specific
random factors had a significant effect in the final model
(b = 1.75, 95% CI 0.85, 3.63, p = 0.007). When including
SHC x time interaction the overall model fit was signifi-
cantly reduced and this interaction was therefore not in-
cluded in the final model. The final model and estimates
of covariance parameters is presented in Table 1.
The SHC score did not differ significantly between fe-
male AA and *G carriers, F (1, 63) = 1.63, p = 0.206, be-
tween male AA and *G carriers, F (1, 48) = 2.48, p = 0.122
or between female and male AA carriers, F (1, 88) = 0.63,
p = 0.43.
Discussion
The present study shows that multiple subjective health
complaints (SHC) are associated with the OPRM1 poly-
morphism. During the study time span female *G car-
riers reported significantly higher SHC scores than male
Figure 1 Subjective health complaints and pain scores (mean values ± SEM) according to sex and genotype.
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intensity and prior duration of pain. Hence, the present
data demonstrate that SHC may be a trait that in itself is
linked to the OPRM1 genotype. Moreover, our results
show that SHC in patients with lumbar radicular pain
and disc herniation are associated with a specific sex -
OPRM1 polymorphism interaction. Previous data demon-
strate an increase in SHC in patients with longer duration
of radicular pain, indicating SHC to be secondary to pain
and disability [2]. Our analyses however, suggest that the
increased SHC might be more than just a phenomenon
secondary to pain. No difference was found between fe-
male AA and *G carriers, male AA and *G carriers or
female and male carriers of the AA genotype.
The sex - OPRM1 polymorphism interaction observed
in the present study clearly support earlier findings. For
example, it has been reported that μ-opioid receptor
binding potential may be higher with increasing age and
in women [33]. Moreover, in one human experimental
study, region-specific differences in OPRM1 levels be-
tween individuals with AA and G alleles have been dem-
onstrated [34]. Additionally, the OPRM1 genotype may
influence stress responses, immune and pro-inflammatory
responses [21,35-37], and reactivity to social rejection
[27]. Also, acute and chronic stress has been suggested to
affect available μ-opioid receptor pools in GABAergic in-
terneurons differentially in female and male rats [38].
Exactly how this happens is not fully understood.
It is, however, now well established that the OPRM1
polymorphism leads to a substitution of the amino acid
asparagine (N) to aspartic acid (D) at position 40 of the
extracellular receptor region. This affects the glycosyla-
tion site of the receptor, which is important for cellular
processes such as receptor folding, sorting, expression
and ligand binding [39]. The level and type of glycosyla-
tion are different between female and male mice [40-42],
which may explain the sex-differences [43]. Hence,
we think the OPRM1 polymorphism in a sex-specificmanner also may affect supraspinal neuronal signal-
ing in humans.
The SHC Inventory captures similar symptoms as de-
scribed in phenomenon such as medically unexplained
symptoms or somatisation [5,7,9]. Somatisation symp-
toms, when not adequately explained by organic findings,
have been conceptualised as either I) somatic manifest-
ation of psychological distress, II) or as somatic distress
and the experience of medically unexplained symptoms
without a strong assumption about causality, or III) as
somatic syndromes characterised by specific clusters of
somatic symptoms [44,45]. The present study cannot dif-
ferentiate between these concepts, but gives support to
the argument that we should avoid simple psychological
explanations of these physical complaints [8]. Previous
findings have shown a similar association between a
five-item questionnaire pertaining to unexplained som-
atic symptoms in the general population and genes
relevant for the neuroendocrine system [46]. Taken to-
gether, genetically mediated variance of these com-
plaints suggests that physiological processes influenced
by genotype may be explanatory in some individuals’
symptom phenotype.
Duration of pain prior to baseline was an independent
predictor for SHC in the present study. The female *G
carriers had on average 23 weeks longer duration than
male *G carriers. It is possible that duration of pain in-
fluenced the progress in SHC and pain scores - and that
with longer durations also men would report increasing
subjective health complaints. It has been shown in a
similar cohort with lumbar radicular pain patients that
those who report their pain as unchanged or worse, also
report subjective health complaints as significantly ele-
vated [2]. It is also possible that female *G carriers seek
medical help at a later stage. However, female AA car-
riers had over 10 weeks longer duration than male AA
carriers, without differing SHC scores. Moreover, male
*G carriers had a shorter pain duration before inclusion
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faster recovery of their pain.
Previous studies have reported that individuals with
one or more G-alleles have a reduced analgesic response
to opioids. Thus, our lack of data on medication may be
a potential confounder [15,47]. Moreover the inherent
uncertainty in interpretation of genetic association stud-
ies and the low numbers of *G carriers emphasises the
need for replication of our findings. Importantly, the fre-
quency of G-variant carriers in the general population is
low, 10.4% among Caucasians has been reported [12].
The present finding can therefore only explain some of
the variance of subjective health complaints in total.
Conclusion
The present data indicate that SHC in patients with ra-
dicular pain and disc herniation may be influenced by a
polymorphism in the OPRM1 gene in a sex-specific man-
ner. We conclude that SHC may be a trait that in itself is
linked to the OPRM1 genotype.
Additional file
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